Physician Views snap poll: Will safety concerns slow early adoption of Novartis' Beovu?

The catalyst: Touted as a potential blockbuster by Novartis, the wet-age related macular degeneration (AMD) treatment Beovu could now face barriers to adoption following release of a safety notification by the American Society of Retina Specialists (ASRS), analysts have warned. Particularly as Regeneron’s Eylea is a well-established incumbent and alternative therapy option.

The poll: Following its approval by the FDA in October last year, we are snap-polling US-based ophthalmologists who have prescribed Beovu previously how the ASRS update may shape their future utilisation habits…

Q. Have you previously prescribed Beovu (brolucizumab) for the treatment of wet age-related macular degeneration (AMD)?

Yes

No

_____________

Q. On a scale of 1 to 5, to what extent has the launch of Beovu incrementally improved the treatment paradigm for wet AMD?

1 – None             2            3            4            5 – Significantly

_____________

Q. The American Society of Retina Specialists (ASRS) issued an update regarding Beovu on February 23 noting that since its approval on October 7, 2019, there have been 14 reported cases of vasculitis, with 11 reported to be occlusive retinal vasculitis. Approximately 46,000 Beovu injections have been administered to date in the US.

What impact do you anticipate the ASRS update will have on your own personal use of Beovu in patients who are already receiving treatment with the drug?

Stop use altogether

Proceed with significant caution

Proceed with some caution

Use to continue as normal

_____________

Q. What impact do you anticipate the ASRS update will have on your own personal use of Beovu in patients who are candidates for treatment with the drug, but have yet to receive it?

Stop planned use altogether

Proceed with significant caution

Proceed with some caution

Plan to use as normal

_____________

Q. Taking into consideration access to other available therapies for wet AMD, do you think this update from the ASRS will limit the utilisation of Beovu in the long term?

No

Yes – Marginally

Yes – Moderately

Yes – Significantly 

_____________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.